This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

G1 Therapeutics 의 총 주주 지분은 $24.6M 이고 총 부채는 $44.3M, 이는 부채 대 자기자본 비율을 180.2% 로 가져옵니다. 총자산과 총부채는 각각 $98.7M 및 $74.1M 입니다.

주요 정보

180.2%

부채 비율

US$44.32m

부채

이자 보상 비율	n/a
현금	US$60.73m
주식	US$24.59m
총 부채	US$74.10m
총 자산	US$98.69m

최근 재무 상태 업데이트

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

재무 상태 분석

단기부채: GTHX 의 단기 자산 ( $92.9M )이 단기 부채( $37.5M ).

장기 부채: GTHX 의 단기 자산( $92.9M )이 장기 부채( $36.6M ).

부채 대 자본 내역 및 분석

부채 수준: GTHX 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: GTHX 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 180.2% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: GTHX 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: GTHX 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

건강한 기업 발견하기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/09/18 09:20
장 마감 주가	2024/09/18 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

G1 Therapeutics, Inc. 8 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Harshita Polishetty	B. Riley Securities, Inc.
Dane Leone	BTIG
Charles Butler	D. Boral Capital LLC.

This company has been acquired

G1 Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Recent updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.39 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

New major risk - Share price stability

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 10.0% to US$7.50

G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

CEO, President & Director recently sold US$178k worth of stock

Consensus estimates of losses per share improve by 18%

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 22%

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 12% to US$8.33

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC

CEO, President & Director recently sold US$108k worth of stock

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

New minor risk - Share price stability

G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

Consensus EPS estimates upgraded to US$0.96 loss

Price target decreased by 21% to US$8.80

New minor risk - Market cap size

New minor risk - Profitability

No longer forecast to breakeven

Consensus estimates of losses per share improve by 29%

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate

Consensus revenue estimates increase by 26%

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023

Consensus EPS estimates upgraded to US$2.01 loss, revenue downgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1)

Price target decreased by 45% to US$16.40

CEO, President & Director recently sold US$219k worth of stock

G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

CEO, President & Director notifies of intention to sell stock

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer

G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million.

Price target decreased to US$32.86

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc)